peptide clinics FAQ

Request the batch-specific HPLC chromatogram and mass spectrometry report from your supplier immediately. Compare the molecular weight on the MS report to the theoretical weight of the intended peptide. A discrepancy indicates sequence truncation or deletion peptides. Check the HPLC purity: anything below 95% suggests significant impurity content that could interfere with receptor binding or enzymatic activity. If your supplier cannot provide batch-specific documentation, the peptide's synthesis history is unverifiable and the potency issue cannot be diagnosed.

Lyophilized peptides should appear as fine white or off-white powder. Clumping suggests moisture exposure from inadequate sealing or temperature cycling during storage. Discoloration (yellow, brown) indicates oxidation of aromatic amino acids like tryptophan or tyrosine, which alters receptor binding properties. Don't attempt to use discolored peptides in biological assays. Contact the supplier with photographs and request a replacement batch. Real Peptides visually inspects every vial before shipment and guarantees peptide appearance matches the expected lyophilization profile for that sequence.

Peptides shipped without cold chain monitoring may have experienced temperature excursions degrading potency. Lyophilized peptides tolerate brief ambient temperature exposure (24–48 hours at 20–25°C), but extended heat exposure accelerates aggregation and oxidation. If the package arrived warm or shipping took longer than expected, contact the supplier with tracking information and request temperature logger data if available. We ship temperature-sensitive peptides like Tesofensine with gel ice packs and insulated packaging to maintain 2–8°C during transit—temperature abuse isn't the researcher's fault and shouldn't be their cost.

Context determines whether this is acceptable. For peptides used in dose-response studies, receptor affinity assays, or enzymatic activity measurements. Where minor impurities (truncated sequences, deletion peptides, or residual synthesis reagents) can alter binding kinetics. 95% purity introduces too much variability. Insist on ≥98% purity verified through HPLC with a clearly defined impurity profile. For general cell culture work or preliminary screening studies, 95% may be sufficient if the supplier documents what comprises the remaining 5%. Acceptable impurities include residual TFA (trifluoroacetic acid) or acetate salts, but unacceptable impurities include peptide fragments or aggregated species.

Request the 503B facility name in writing. Legitimate providers disclose this immediately because it's basic supply chain transparency. If they refuse, cite concerns about recent FDA enforcement actions and compounding facility contamination cases. Refusal suggests sourcing from unverified 503A pharmacies, grey-market importers, or facilities with compliance issues. Switch providers. No legitimate clinical reason exists to withhold facility information.

Request the information in writing. Any legitimate provider prescribing compounded peptides will disclose the name and FDA registration number of their 503B partner pharmacy without hesitation. If the provider deflects, claims proprietary sourcing, or refuses to answer, the peptides are likely sourced from an unregistered compounding pharmacy or resold without verifiable origin. The risk is not theoretical: unregistered compounders have been linked to contamination events resulting in bacterial infections, incorrect dosing, and peptide degradation due to improper storage. Without 503B documentation, you have no assurance the peptide you receive matches the prescription written or meets sterility standards.

Request documentation showing FDA approval status for the specific compound. BPC-157 and Thymalin are research chemicals without FDA approval as prescription drugs, meaning Tennessee prescribers cannot legally write prescriptions for them under current pharmacy law. Clinics that 'prescribe' these compounds are either operating outside Tennessee Board of Pharmacy jurisdiction (by shipping from research suppliers, not pharmacies) or misrepresenting research chemicals as compounded medications. If a clinic insists these are prescription drugs, verify the dispensing pharmacy's 503B registration or Tennessee pharmacy license. Research chemical suppliers cannot issue prescription labels.

This violates Pennsylvania prescribing standards because an FDA-approved equivalent exists for the same indication (type 2 diabetes and weight management). Research-grade peptides are legally prescribed only when no approved drug targets the same pathway. If cost is the barrier, compounded tirzepatide from a 503B facility during FDA shortages is the appropriate alternative. Not research-grade peptides intended for laboratory use.

Stop the protocol immediately. GLP-1 agonists require baseline and quarterly monitoring of lipase (pancreatitis risk), thyroid function (medullary thyroid carcinoma screening), and kidney function (dose adjustment for renal impairment). BPC-157 and thymosin beta-4 lack standardised monitoring protocols because they're not FDA-approved, but responsible providers still check inflammatory markers and injury-site imaging at 4–6 week intervals. A clinic that prescribes without follow-up labs isn't practising medicine. It's selling compounds.

Reschedule within one week if you're on GLP-1 peptides or growth hormone secretagogues. Metabolic and endocrine markers change rapidly, and dose adjustments depend on current lab values. For tissue repair peptides like BPC-157 or thymosin beta-4, missing one 8-week checkpoint is less critical, but extending beyond 12 weeks without labs risks missing adverse trends. Most telehealth platforms allow you to order labs through LabCorp or Quest at any location. Results upload directly to your provider portal.

Discard it immediately. Do not inject. Cloudiness indicates incomplete dissolution due to low purity (typically below 90%), contamination, or degraded product. Genuine high-purity lyophilised peptides produce a clear solution within 60 seconds of mixing with bacteriostatic water. Cloudiness means truncated peptide chains, acetate salt imbalances, or particulate contamination that compromises both safety and efficacy. Contact the supplier with photographic documentation and request batch verification through independent HPLC analysis. Reputable suppliers replace compromised batches without dispute.

Depends on your clinic's pharmacy partnership and remaining inventory. Most 503B facilities halted semaglutide compounding in February 2026 when the FDA shortage exemption ended. If your clinic was sourcing from a compliant 503B facility, they likely transitioned you to branded Wegovy or stopped prescribing entirely. Some clinics are using remaining inventory from pre-cutoff batches. That inventory is legal to dispense until expiration, typically 90–180 days from compounding date. Ask your clinic for the compounding date on your vial and the FDA registration number of the 503B facility that produced it. If they cannot provide that information, you are likely receiving product from a non-compliant source.

Refuse to purchase or use the compound. Every legitimate peptide supplier. Whether compounding pharmacy, research distributor, or prescribing clinic. Must provide a certificate of analysis documenting purity, molecular weight, and endotoxin levels for the specific batch being dispensed. Absence of a COA signals either unregulated bulk distribution or a supplier unwilling to document product specifications. In 2026, this is a non-negotiable quality marker. Peptide clinics Nevada providers services 2026 operating without COA transparency are bypassing the most basic accountability standard in the industry.

Contact the provider and request the certificate of analysis (CoA) showing HPLC purity testing, lot number, and manufacturing date. Legitimate 503B facilities provide CoAs for every batch. If the provider cannot produce one, the peptide was sourced from an unregistered compounder or overseas supplier. Do not administer peptides without verified purity. Structural contamination, incorrect amino acid sequencing, or bacterial endotoxins are invisible but clinically significant. If the provider claims proprietary sourcing or cannot verify the compounder's registration status, consider the peptide unverified.

Request the name and FDA registration number of the 503B facility or the Maryland pharmacy license number if sourcing from a state-licensed compounder. A legitimate clinic provides this within 24–48 hours. It's public information and a standard patient safety disclosure. If the clinic refuses or claims proprietary sourcing, that's a hard stop. Unverified peptide sources carry risks including bacterial contamination, incorrect active ingredient concentrations, or complete absence of the stated compound. No peptide therapy is worth bacterial endotoxin exposure or dosing errors that could trigger hypoglycemia or pancreatitis.

Request COAs in writing before starting therapy. If the clinic refuses or claims "proprietary supplier agreements" prevent disclosure, end the consultation and find a different provider. Legitimate peptide suppliers like Real Peptides publish COAs for every batch. There's no valid reason for a clinic to withhold them. The absence of purity documentation means you're injecting a substance of unknown composition, which isn't acceptable risk even for off-label peptide use.

Request your current dosing schedule and confirm your peptide clinic can match it. Branded Ozempic delivers semaglutide in prefilled pens with fixed-dose increments (0.25mg, 0.5mg, 1mg, 2mg weekly). Compounded versions come in multi-dose vials requiring manual syringe measurement, which introduces dosing variability if you're unfamiliar with injection technique. The active molecule is identical, but compounded formulations may use different excipients affecting absorption slightly. Most patients transition without issue, but the first month requires closer symptom monitoring for GI side effects that indicate under- or over-dosing.

Contact the supplier immediately and request the batch-specific CoA before using the compound. A missing CoA means you have no documented verification of purity, molecular weight, or sterility. Using the peptide without this documentation introduces an uncontrolled variable that can invalidate your entire study. Real Peptides includes lot-specific HPLC reports and molecular weight confirmation in every shipment; if a CoA is missing, we resend it within 24 hours or replace the order. Never assume a peptide is correctly synthesized based on appearance alone. Colorless, clear solutions can still contain truncated sequences or amino-acid substitutions.

Compounded peptides are excluded from most commercial insurance formularies because they are not FDA-approved finished drug products. Some patients have successfully obtained reimbursement by submitting claims under off-label prescription codes with supporting documentation from their prescriber, but approval rates are below 15% even with prior authorization. The most reliable cost-reduction strategy is enrolling in a clinic's subscription model, which bundles consultation, lab review, and medication into a flat monthly fee. This typically reduces per-month costs by 20–30% compared to pay-per-service pricing.

Many investigational peptides. Thymalin for immune modulation, MK 677 for growth hormone secretion research, P21 for neuroprotection studies. Exist only as research compounds. No prescription pathway exists because no FDA approval exists. Researchers access these through suppliers selling peptides labeled for investigational use only. Real Peptides specialises in this category, providing high-purity peptides with exact amino-acid sequencing and third-party testing documentation. Buyers handle reconstitution, dosing, and application independently. This model works for informed researchers conducting non-clinical studies but carries full liability. No prescriber involvement, no insurance coverage, and no clinical validation of efficacy or safety for therapeutic use.